Astragaloside IV (AS-IV) is an active component of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV has been reported to alleviate vascular endothelial dysfunction and promote angiogenesis. However, its function in hypertensive heart disease (HHD), a key underlying mechanism for cardiovascular morbidity and mortality, remains to be defined. The objective here is to investigate the inhibiting effect of AS-IV on HHD. HHD mice were induced by N(omega)-nitro-L-arginine methyl ester (L-NAME, LN), followed by AS-IV treatment. LN caused arterial endothelial dysfunction and cardiomyocyte injury in mice, while AS-IV ameliorated the pathological changes. Moreover, LN reduced the viability of arterial endothelial cells and cardiomyocytes and diminished the migration and angiogenic capacity of arterial endothelial cells, which were alleviated by AS-IV. AS-IV ameliorated LN-induced loss of retinoic acid receptor RXR-alpha (RXRA) and promoted the transcription of sirtuin 3 (SIRT3) via the RXRA/peroxisome proliferator-activated receptor gamma (PPARG) heterodimer. Knockdown of RXRA resulted in a loss of the therapeutic effect of AS-IV, and the progression of HHD caused by knockdown of RXRA was reversed by PPARG or SIRT3 overexpression. Hence, we propose that AS-IV promotes the expression of RXRA in HHD and mediates the transcription of SIRT3 through RXRA/PPARG, thereby ameliorating endothelial dysfunction and cardiomyocyte injury. KEY MESSAGES: AS-IV inhibits LN-induced HHD in mice and cardiomyocyte injury. AS-IV promotes endothelial cell migration and angiogenesis. AS-IV inhibits the loss of RXRA expression induced by LN. RXRA/PPARG heterodimer regulates the transcriptional expression of SIRT3. The therapeutic effect of AS-IV on HHD is dependent on RXRA/PPARG/SIRT3 signaling.

2026-07-01·BIOMATERIALS

DNA tetrahedron-mediated vascular targeted delivery of astragaloside IV enhances distraction osteogenesis via PI3K/AKT/FOXO pathway

Article

作者: Zhu, Peiqi ; Wang, Xudong ; Wei, Hongpu ; Fu, Haojie ; Huang, Xuanping ; Hong, Shebin ; Wu, Hao ; Feng, Yisheng ; Jiang, Weidong ; Shang, Yinyu ; Chen, Yanchu

Bone regeneration during distraction osteogenesis (DO) remains limited by insufficient vascularization, which delays consolidation and compromises clinical outcomes. Here, we developed a vascular-targeted DNA nanoplatform (TDN@Ast-AptCD34) for the delivery of Astragaloside IV (Ast), a natural compound with pro-angiogenic and osteogenic properties. The nanoplatform integrated a DNA tetrahedron carrier with a vascular-targeting aptamer (AptCD34) and was further incorporated into a biocompatible mHA-PVA hydrogel for localized and sustained release. Physicochemical analyses confirmed its stable structure, efficient Ast encapsulation, and enhanced uptake by endothelial progenitor cells (EPCs). Functionally, TDN@Ast-AptCD34 significantly promoted EPC migration, tube formation, and paracrine-mediated osteogenesis of jaw bone mesenchymal stem cells (JBMSCs), thereby reinforcing angiogenesis-osteogenesis coupling. Integrated network pharmacology, RNA sequencing, and molecular dynamics simulations identified PI3K/AKT/FOXO signaling as the central downstream axis. Mechanistically, TDN@Ast-AptCD34 activated PI3K/AKT signaling and relieved FOXO1-mediated repression of angiogenic genes, which was validated by rescue experiments under PI3K inhibition. In vivo, the hydrogel-delivered nanoplatform markedly enhanced early vascularization and robust bone regeneration in a mandibular DO model, whereas these effects were significantly attenuated upon PI3K inhibition by LY294002. Collectively, this study establishes TDN@Ast-AptCD34 as a multifunctional nanoplatform that couples angiogenesis with osteogenesis via PI3K/AKT/FOXO signaling, providing a promising strategy for vascularized bone regeneration in challenging clinical settings.

2026-04-01·CARBOHYDRATE POLYMERS

Pullulan-stabilized gliadin nanocomplexes loaded with astragaloside IV: Fabrication, characterization and treatment of ulcerative colitis

Article

作者: Wang, Xiao ; Chen, Zhimin ; Li, Xiaofang ; Chen, Siyin ; Jia, Qingya ; Li, Ling ; Chen, Liping ; Su, Yufei ; Luo, Kaipei ; Li, Qiuxia ; Yang, Lu ; Liao, Weiwei ; Wu, Yuxin

Astragaloside IV (ASIV) is a triterpenoid saponin with promising potential in treating ulcerative colitis (UC), but its efficacy is hindered by poor solubility and rapid systemic clearance. Gliadin, an amphiphilic protein, has been widely used as a nanocarrier. Here, the novel edible pullulan-stabilized gliadin nanocomplexes (PL-Gli NPs) were developed to deliver ASIV. Interaction force analysis revealed that the formation of PL-Gli NPs involved in electrostatic interaction, hydrophobic interaction, and hydrogen bonding. ASIV was encapsulated into PL-Gli NPs via hydrophobic interaction to form ASIV-loaded nanocomplexes (ASIV@PL-Gli NPs). The resulting nanocomplexes had a particle size of (381.5 ± 5.3) nm and high encapsulation efficiency of 93.00 %. Notably, the stability of ASIV@PL-Gli NPs was improved under harsh conditions owing to the incorporation of pullulan. Furthermore, ASIV@PL-Gli NPs exhibited sustained release, with only 63.69 % cumulative release of ASIV at 10 h. Importantly, ASIV@PL-Gli NPs markedly enhanced anti-UC efficacy of ASIV, evidenced by a 51.81 % increase in colon length, a 53.16 % reduction in disease activity index scores, and significant decreases in pro-inflammatory cytokine levels. This work first employs pullulan and gliadin as oral nanocarriers for the delivery of ASIV, providing great potential for functional foods in UC treatment.

项与 Astragaloside-IV 相关的新闻（医药）

2022-09-26

·BioSpace

Creative Enzymes Announces the Start of Year-End Promotion on Its Kosher Certified Products

Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with enzyme services and products with its greatest effort. Creative Enzymes today announced extensive savings on the full range of Kosher Certified Products in its year-end promotion, which runs until December 29, 2022. Kosher Certification is the stamp of kosher approval by a rabbinic agency verifying checked products ingredients, production facility, and actual production to ensure that all ingredients, derivatives, tools and machinery have no trace of non-kosher substances. The Kosher Certified symbol assures consumers that both the actual product and its production adhere to all Kosher Law requirements. The promotion will enable biologists to save money on premium Kosher-certified products. Creative Enzymes provides the following featured Kosher certified products: Epimedium Extract Epimedium extract, also known as horny goat weed extract, has been used to treat male erectile dysfunction, which enhances sperm production, stimulates nervous sensation, and indirectly promotes sexual desire. Lotus Leaf Extract Lotus leaf extract can significantly reduce serum cholesterol levels of glycerol and glycerol, and plays a role in regulating blood lipid health. Astragalus Extract Astragalus extract astragaloside has been used to promote the discharge of urine, lower blood pressure, and increase endurance. Maca Root Extract Maca root extract powder contains several biologically active components that may help enhance physical energy and endurance. Bilberry Extract Bilberries are rich in anthocyanosides, proanthocyanidins, resveratrol, flavors, and tannins that inhibit cancer cell development and inflammation. Capsicum Extract Capsaicin in capsicum consists of anti-inflammatory and antioxidant effects. Rosemary Extract Rosemary extract reveals growing popularity among certain food producers due to its ability to act as a natural preservative. Native Roxburgh Superoxide Dismutase Superoxide dismutase (SOD) catalyzes the dismutation of superoxide radicals to hydrogen peroxide and molecular oxygen. SOD plays a critical role in the defense of oxygen radicals. “This promotion is definitely a unique offer. For many years, we have been committed to providing our customers with cost-effective and high-quality services and products. We are pleased to offer our customers widely discounted prices on most of our products and are fully aware that only high-quality products can reward their support and trust,” said Creative Enzymes’s Chief Scientist. About Creative Enzymes Creative Enzymes is a remarkable supplier and manufacturer in the enzymology field. Equipped with advanced technology platforms, Creative Enzymes is able to offer high-quality and professional services to customers. Its products and services have been widely used institutionally for academia and industrially for pharmaceuticals. Contact Address: Shirley, NY 11967, USA Email: contact@creative-enzymes.com

100 项与 Astragaloside-IV 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏病	临床前	中国	包头医学院	2025-05-28
肺动脉高压	临床前	中国	锦州医学院	2025-01-01
代谢功能障碍相关的脂肪肝病	临床前	中国	邛崃市中医医院	2024-04-19
药物性心脏毒性	临床前	中国	天津市人民医院	2024-03-16